1. Home
  2. STTK vs MLEC Comparison

STTK vs MLEC Comparison

Compare STTK & MLEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • MLEC
  • Stock Information
  • Founded
  • STTK 2016
  • MLEC 2008
  • Country
  • STTK United States
  • MLEC United Kingdom
  • Employees
  • STTK N/A
  • MLEC N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • MLEC Blank Checks
  • Sector
  • STTK Health Care
  • MLEC Finance
  • Exchange
  • STTK Nasdaq
  • MLEC Nasdaq
  • Market Cap
  • STTK 38.4M
  • MLEC 36.0M
  • IPO Year
  • STTK 2020
  • MLEC N/A
  • Fundamental
  • Price
  • STTK $0.77
  • MLEC $3.18
  • Analyst Decision
  • STTK Hold
  • MLEC
  • Analyst Count
  • STTK 4
  • MLEC 0
  • Target Price
  • STTK $3.00
  • MLEC N/A
  • AVG Volume (30 Days)
  • STTK 229.3K
  • MLEC 153.1K
  • Earning Date
  • STTK 08-04-2025
  • MLEC 08-05-2025
  • Dividend Yield
  • STTK N/A
  • MLEC N/A
  • EPS Growth
  • STTK N/A
  • MLEC N/A
  • EPS
  • STTK N/A
  • MLEC N/A
  • Revenue
  • STTK $4,606,000.00
  • MLEC N/A
  • Revenue This Year
  • STTK N/A
  • MLEC $20.42
  • Revenue Next Year
  • STTK N/A
  • MLEC $30.00
  • P/E Ratio
  • STTK N/A
  • MLEC N/A
  • Revenue Growth
  • STTK 69.65
  • MLEC 170.36
  • 52 Week Low
  • STTK $0.69
  • MLEC $2.99
  • 52 Week High
  • STTK $4.51
  • MLEC $10.47
  • Technical
  • Relative Strength Index (RSI)
  • STTK 41.85
  • MLEC 23.88
  • Support Level
  • STTK $0.73
  • MLEC $2.99
  • Resistance Level
  • STTK $0.92
  • MLEC $3.60
  • Average True Range (ATR)
  • STTK 0.07
  • MLEC 0.46
  • MACD
  • STTK 0.01
  • MLEC -0.04
  • Stochastic Oscillator
  • STTK 20.80
  • MLEC 7.54

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About MLEC Moolec Science SA

Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's revenues arise from operations in Argentina.

Share on Social Networks: